Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy

NCT02638207 is registered in ClinicalTrials.gov with Octapharma as lead sponsor.

NCT NCT02638207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02638207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy
Lead sponsor
Octapharma
Phase
Phase 3
Overall status
Completed
Start date
September 27, 2017
Completion date
September 5, 2019
Enrollment
142 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

chronic inflammatory demyelinating poly(radiculo)neuropathy